Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI

NCT02972333 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT02972333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02972333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2019
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

azd9291, brain metastases, egfr-tki resistant mutation, nonsmall cell lung cancer